Why Arrowhead Pharmaceuticals, Inc.’s (ARWR) Stock Is Down 7.03%
As of Wednesday, September 23, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 7.03%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Arrowhead Pharmaceuticals, Inc. (ARWR)
Arrowhead Pharmaceuticals, Inc. ARWR
$64.19
-0.60
-0.93%
October 2, 2026 4:00:00 PM
EST
Volume: 1,487,624
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Commentary & Analysis
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or CareDx, Inc. Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or CareDx, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or uniQure N.V. Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or uniQure N.V. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Why Arrowhead Pharmaceuticals, Inc.’s (ARWR) Stock Is Down 6.30%
As of Tuesday, September 15, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 6.30%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or BeOne Medicines AG Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or BeOne Medicines AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Financial Summary
| Share Statistics | ARWR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9,067.1 | $250.1 | 77% |
|
| Shares Out (Mil) | 143.4 | 54.0 | 70% |
|
| Institutional Ownership | 95.9% | 93.1% | 68% |
|
| Float (Mil) | 122.4 | 41.4 | 65% |
|
| Beta | 1.29 | 0.95 | 75% |
|
| Avg Daily Volume (000s) | 2,047 | 661 | 81% |
|
| Price Change (52-week) |
83.4% | 49.5% | 91% |
|
| Growth | ARWR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 56.6% | 12.5% | 97% |
|
| Net Income (5yr) | 54.8% | (10.1%) | 95% |
|
| EPS (5yr) | 57.2% | 15.8% | 95 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 26.1% | (15.7%) | 84% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 14 | 14 | 14 | |
| Current EPS | ($1.535) | ($3.540) | ($4.931) | |
| Month Ago EPS | ($1.593) | ($3.607) | ($4.831) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($1.125) | ($3.002) | ($4.336) | |
| Year/Year Chg | 12.9% | 29,400% | 27,383% | |
| Financials | ARWR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $670 | $37 | 44% |
|
| Net Income (TTM) (Mil) | ($320) | ($44) | 4% |
|
| EPS (TTM) | ($2.278) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($59) | ($33) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($75) | $2 | 17% |
|
| Long-Term Debt (Q1) (Mil) | $1,331 | $4 | 69% |
|
| Enterprise Value (Q1) (Mil) | $12,087 | $175 | 77% |
|
| Valuation | ARWR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 19.45 | 2.36 | 96% |
|
| P/E | na | 18.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ARWR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.3% | 96% |
|
| Net Margin | (47.8%) | (74.8%) | 12% |
|
| ROA | (18.3%) | (47.6%) | 21% |
|
| ROE | (64.8%) | (54.9%) | 13% |
|
| Liabilities to Assets | 77.9% | 29.3% | 73% |
|
| F-Score | 2 | 3 | 7% |
|
Arrowhead Pharmaceuticals, Inc. did not pass any screens on 10/2/2026.
